Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-4208 multiple-dose crossover study in COPD
ACTRN12612001235897Phase 2Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of revefenacin in chronic obstructive pulmonary disease (COPD), sponsored by Theravance Biopharma, Inc. Primary endpoint: Trough FEV1. Started Dec 2012; status: completed.
02
Drugs
revefenacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ACTRN12612001235897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001235897.